Cardiff Oncology shares plunge after Q2 earnings miss
Marsh & McLennan Companies, Inc. (MMC) has reached an all-time high, with its stock price soaring to $247.71. This new peak marks a significant milestone for the global professional services firm, specializing in risk, strategy, and people. Over the past year, MMC has witnessed a robust performance, delivering a 23.5% total return while maintaining its 55-year streak of consistent dividend payments, with a current yield of 1.33%. The company’s ascent to this record level underscores investor confidence and the successful execution of its strategic initiatives amidst a complex and evolving global market landscape. With revenue growth of 7.6% and an EBITDA of $7.2 billion in the last twelve months, MMC continues to demonstrate strong fundamentals. InvestingPro subscribers can access 12 additional key insights about MMC’s performance and outlook.
In other recent news, Marsh & McLennan Companies announced a quarterly dividend of $0.815 per share, set to be paid on May 15, 2025, to shareholders recorded by April 3, 2025. This announcement underscores the company’s commitment to providing returns to its investors. Additionally, Marsh McLennan (NYSE:MMC) Agency has expanded its reach by acquiring Arthur Hall Insurance, enhancing its business insurance capabilities and establishing a new presence in Delaware. The acquisition aims to bolster Marsh McLennan Agency’s service offerings and expertise across various industries.
In another development, Mercer (NASDAQ:MERC), a subsidiary of Marsh McLennan, has agreed to acquire SECOR Asset Management, a global investment firm. This acquisition, pending regulatory approvals, is expected to complete in the second quarter of 2025 and will enhance Mercer’s investment solutions for institutional investors. Meanwhile, Raymond (NSE:RYMD) James has maintained its Outperform rating for Marsh & McLennan, with a price target of $250.00. The firm’s analyst highlighted the company’s potential for organic growth and margin expansion compared to its peer AON through 2025.
Raymond James also updated its earnings estimates for Marsh & McLennan, projecting adjusted EPS of $9.45 for 2025 and $10.20 for 2026, following a revision in the company’s EPS definition. These developments reflect Marsh & McLennan’s strategic moves to strengthen its market position and deliver value to its stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.